At last, these results offer momentous initiatory evidence on the role of SHD in glioma treatment with a multiple-target pattern and suggest that SHD may be a promising candidate to raise TMZ sensitiveness for GMB treatment. This evidence concerns the gene SHD and central nervous system cancer.